Epigenetic silencing of MGMT via promoter methylation predicts response to temozolomide and nitrosoureas and may also be a positive prognosticator independent of treatment.22–25 While tumor MGMT promoter methylation data is incomplete for our trial population, 8/9 (89%) patients with known status were unmethylated. The gene discussed is MGMT; the disease is neoplasm.